Litigation Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
✉ Email this page to a colleague
Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-10-24 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 7,232,818; 7,417,042; 7,737,112; 8,207,125 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-05-04 | 546 | Opinion | 1035-37) 95. U.S. Patent 7,232,818 (“the ’818 Patent), which is not asserted in the instant… Onyx’s U.S. Patent Nos. 7,417,042 (“the ’042 Patent”) and 8,207,125 (“the ’125 Patent”) (collectively… “the Compound Patents”) as well as Onyx’s U.S. Patent No. 7,737,112 (“the ’112 Patent” or “the Formulation…Formulation Patent” and, together with the Compound Patents, “the Asserted Patents”). (See D.I. 1; see also… 24 of the ’042 Patent, claim 1 of the ’125 Patent, and claim 31 of the ’112 Patent are not invalid for | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
